Results of a prospective, single-arm, multicentre, phase 2 trial suggest that pazopanib might have activity in patients with unresectable or metastatic liposarcoma, a rare malignancy with poor prognosis. Pazopanib is a multi-targeting tyrosine kinase inhibitor approved as second-line therapy for other types of soft tissue sarcoma.

中文翻译：

---

帕唑帕尼治疗晚期脂肪肉瘤

一项前瞻性，单臂，多中心，2期试验的结果表明，帕唑帕尼可能在无法切除或转移性脂肪肉瘤的患者中具有活性，这是一种罕见的恶性肿瘤，预后较差。帕唑帕尼是一种多靶点酪氨酸激酶抑制剂，被批准作为其他类型的软组织肉瘤的二线治疗药物。